{"article_id": "DHR_q1_2021.txt", "article": ["we generated $ 6.9 billion of sales in the first quarter with 30 % core revenue growth .", "we saw over 20 % growth in the developed market , led by north america and western europe .", "high - growth markets were up more than 45 % , largely driven by the recovery in china .", "our gross profit margin increased 580 basis points year - over - year to 62 % in the first quarter , largely due to higher sales volumes and the positive impact of higher - margin product mix .", "our operating profit margin of 29.1 % was up 1,300 basis points year - over - year , including more than 900 basis points of core margin expansion as a result of higher gross margins and lower operating expenses as we continue to see limited travel and other related costs .", "adjusted diluted net earnings per common share of $ 2.52 were up 140 % versus last year .", "we generated $ 1.6 billion of free cash flow in the quarter , an increase of 135 % year - over - year .", "now in the first quarter , we deployed more than $ 400 million of capital toward mergers and acquisitions across all three segments .", "between these four businesses , we 're investing more than $ 1 billion in 2021 to continue to meet our customers ' needs today and well into the future .", "life sciences reported revenue increased 115 % as a result of the cytiva acquisition , and core revenue was up 41.5 % .", "in our bioprocessing businesses , accelerating demand for covid - related vaccines and therapeutic development and production drove a combined core revenue growth rate of more than 60 % at cytiva and pall biotech .", "reported revenue was up 34 % , and core revenue grew 31 % .", "each of our largest operating companies in the platform achieved high single digit or better core revenue growth , led by cepheid , which achieved more than 90 % core revenue growth .", "in response to the unprecedented demand for cepheid 's rapid point - of - care molecular test , the team again increased production capacity and shipped over 10 million respiratory test cartridges in the first quarter .", "roughly half of the tests shipped were covid - only tests , and the other half were 4 - in - 1 combination test for covid - 19 flu a , flu b and rsv .", "reported revenue grew 6.5 % and core revenue was up 3.5 % .", "additionally , we expect to have operating profit fall - through of approximately 40 % in the second quarter and for the remainder of 2021 .", "this would include an estimated $ 2 billion of 2021 revenue at cytiva and pall biotech associated with vaccines and therapeutics , which is higher than our previous expectation of $ 1.3 billion .", "and at cepheid , we 'll continue ramping capacity through the year and now expect to ship approximately 45 million tests in 2021 compared to our prior estimate of 36 million tests ."], "summary_gold": "q1 adjusted non -gaap earnings per share $ 2.52 .<q>q1 revenue rose 58 percent to $ 6.9 billion .<q>for q2 2021 , company anticipates that non -gaap core revenue growth will be in mid-20 percent range .<q>for full year 2021 , company now anticipates that non -gaap core revenue growth rate including cytiva will be in high - teens percent range .", "summary_pred": "adjusted diluted net earnings per common share of $ 2.52 were up 140 % versus last year .<q>reported revenue was up 34 % , and core revenue grew 31 % .<q>this would include an estimated $ 2 billion of 2021 revenue at cytiva and pall biotech associated with vaccines and therapeutics , which is higher than our previous expectation of $ 1.3 billion .<q>our operating profit margin of 29.1 % was up 1,300 basis points year - over - year , including more than 900 basis points of core margin expansion as a result of higher gross margins and lower operating expenses as we continue to see limited travel and other related costs .<q>in response to the unprecedented demand for cepheid 's rapid point - of - care molecular test , the team again increased production capacity and shipped over 10 million respiratory test cartridges in the first quarter .<q>each of our largest operating companies in the platform achieved high single digit or better core revenue growth , led by cepheid , which achieved more than 90 % core revenue growth .<q>roughly half of the tests shipped were covid - only tests , and the other half were 4 - in - 1 combination test for covid - 19 flu a , flu b and rsv .<q>high - growth markets were up more than 45 % , largely driven by the recovery in china .<q>and at cepheid , we 'll continue ramping capacity through the year and now expect to ship approximately 45 million tests in 2021 compared to our prior estimate of 36 million tests .<q>between these four businesses , we 're investing more than $ 1 billion in 2021 to continue to meet our customers ' needs today and well into the future .<q>additionally , we expect to have operating profit fall - through of approximately 40 % in the second quarter and for the remainder of 2021 .", "len_article": 19, "len_summary_gold": 4, "len_summary_pred": 11, "len_sent_scores": 19}